Ptc Therapeutics Stock Investor Sentiment

PTCT Stock  USD 52.59  0.21  0.40%   
Slightly above 55% of PTC Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding PTC Therapeutics suggests that many traders are impartial. PTC Therapeutics' investing sentiment can be driven by a variety of factors including economic data, PTC Therapeutics' earnings reports, geopolitical events, and overall market trends.

Comfort Level 45

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use PTC Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward PTC Therapeutics.
74.0%
16.0%
0.0%

PTC Historical Sentiment

Although PTC Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding PTC, such as negative comments on social media and news outlets, may cause fear in the market and push PTC Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of PTC.
  

PTC Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards PTC Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
63.0%
58.4%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

PTC Therapeutics Historical Investor Sentiment

Investor biases related to PTC Therapeutics' public news can be used to forecast risks associated with an investment in PTC. The trend in average sentiment can be used to explain how an investor holding PTC can time the market purely based on public headlines and social activities around PTC Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
News FrequencyInvestor Sentiment
PTC Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for PTC Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average PTC Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on PTC Therapeutics.

PTC Therapeutics Maximum Pain Price Across April 17th 2025 Option Contracts

PTC Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of PTC Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of PTC Therapeutics' options.
Calls PricePuts Price
over two months ago at investors.com         
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntingtons Drug
Investors Business Daily at Macroaxis
over two months ago at zacks.com         
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
zacks News
over three months ago at benzinga.com         
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
benzinga news
over three months ago at gurufocus.com         
Insider Sell Alert Christine Utter Sells 17,800 Shares of PTC Therapeutics Inc
Gurufocus Stories at Macroaxis
over three months ago at thelincolnianonline.com         
Insider Selling PTC Therapeutics, Inc. CAO Sells 17,800 Shares of Stock
news
over three months ago at thelincolnianonline.com         
PTC Therapeutics, Inc. Director Sells 1,236,000.00 in Stock
news
over three months ago at gurufocus.com         
Insider Sell Alert Jerome Zeldis Sells 24,000 Shares of PTC Therapeutics Inc
Gurufocus Stories at Macroaxis
over three months ago at investing.com         
Disposition of 600 shares by Mark Boulding of PTC Therapeutics at 33.02 subject to Rule 16b-3
Investing News at Macroaxis
over three months ago at investing.com         
Ptc Therapeutics chief technical officer sells shares worth 3.6 million
Investing News at Macroaxis
over three months ago at thelincolnianonline.com         
PTC Therapeutics Given New 32.00 Price Target at Citigroup
news
over three months ago at investing.com         
Disposition of 600 shares by Mark Boulding of PTC Therapeutics at 33.02 subject to Rule 16b-3
Investing News at Macroaxis
over three months ago at thelincolnianonline.com         
PTC Therapeutics Hits New 1-Year High on Analyst Upgrade
news
over three months ago at finance.yahoo.com         
PTCT Stock Soars on Licensing Deal With NVS for Huntingtons Therapy
Yahoo News
over three months ago at zacks.com         
PTCT Stock Soars on Licensing Deal With NVS for Huntingtons Therapy
zacks News
over three months ago at thelincolnianonline.com         
PTC Therapeutics Stock Price Expected to Rise, Robert W. Baird Analyst Says
news
Far too much social signal, news, headlines, and media speculation about PTC Therapeutics that are available to investors today. That information is available publicly through PTC media outlets and privately through word of mouth or via PTC internal channels. However, regardless of the origin, that massive amount of PTC data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PTC Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PTC Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PTC Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PTC Therapeutics alpha.

PTC Therapeutics Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.151234567891011Dec2025Feb -50510152025
JavaScript chart by amCharts 3.21.15PTC Therapeutics PTC Therapeutics Dividend Benchmark Dow Jones Industrial
       Timeline  
1
PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone
12/19/2024
2
Acquisition by Klein Matthew B. of 175000 shares of PTC Therapeutics at 46.54 subject to Rule 16b-3
01/03/2025
3
Disposition of 107 shares by Neil Almstead of PTC Therapeutics at 44.5 subject to Rule 16b-3
01/08/2025
4
Acquisition by Eric Pauwels of 55000 shares of PTC Therapeutics at 46.54 subject to Rule 16b-3
01/17/2025
5
Camber Capital Management LLCs Strategic Acquisition of PTC Therapeutics Inc Shares
02/14/2025
6
Disposition of 1265 shares by Neil Almstead of PTC Therapeutics at 45.34 subject to Rule 16b-3
02/24/2025
7
PTC Therapeutics Inc Q4 2024 Everything You Need To Know Ahead Of Earnings
02/26/2025
8
PTC Therapeutics Reports Q4 Loss, Lags Revenue Estimates
02/27/2025
9
PTC Therapeutics Inc Q4 2024 Earnings Call Highlights Strong Financial Performance and ...
02/28/2025
10
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
03/03/2025
11
Insider Sell Allan Jacobson Sells Shares of PTC Therapeutics Inc
03/07/2025

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.